Clinical trials: Postpartum Depression
Depression, Postpartum
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
- Trial name
- NCT04442503
- Testing
- SAGE-217
- Where
- 82 sites in United States, Spain and 1 more
- Volunteers
- 200 people
- Sponsor
- Biogen
Postpartum Depression
Effect of Consuming a Combination of Probiotic Strains on Postpartum Depression
The objective of this trial is to evaluate the effect of consuming a combination of Lactobacillus during the pregnancy and lactation period on the incidence of postpartum depression.
- Trial name
- NCT06651424
- Testing
- Combination of Lactobacillus probiotics (no comercial)
- Where
- 3 sites in Spain
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Postpartum Depression
A Six-Month Prospective Follow-Up Study of WB001
This study is a 6-month follow-up study to WB001-001 conducted to assess and evaluate the durability of the effect of {WB001+TAU} beyond the 8-week treatment period.
- Trial name
- NCT05693792
- Testing
- Observational
- Sponsor
- Woebot Health
Depression, Postpartum, Postpartum Depression (PPD)
Brexanolone Lifting Outcomes Of Moms
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
- Trial name
- BLOOM (NCT07822321)
- Testing
- LPCN 1154A
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Lipocine Inc.
Postpartum Depression
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression (PPD).
- Trial name
- NCT02285504
- Testing
- SAGE-547
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Postpartum Depression
Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression
This is an expanded access program intended to provide access to ZULRESSO™ (brexanolone) injection for the treatment of a limited number of eligible women with postpartum depression during the period prior to commercial…
- Trial name
- NCT03924492
- Testing
- ZULRESSO (brexanolone) injection
- Sponsor
- Supernus Pharmaceuticals, Inc.
Post Partum Depression
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
This is a multi-center study evaluating the safety, tolerability, and pharmacokinetics of brexanolone in the treatment of adolescent female participants with postpartum depression (PPD).
- Trial name
- NCT03665038
- Testing
- Brexanolone
- Where
- 17 sites in United States
- Volunteers
- 28 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
COVID-19, Pregnancy Complications
Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic
The purpose of this study is to assess the health and wellbeing of pregnant and recently pregnant women during the COVID-19 pandemic using an online survey.
- Conditions
- COVID-19, Pregnancy Complications, Mental Health Wellness 1, Anxiety
- Trial name
- NCT04385238
- Testing
- This is an online survey with no intervention.
- Where
- United States
- Volunteers
- 6,894 people
- Sponsor
- Pregistry
Postpartum Depression
A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)
In this Phase 4 study, women who have been prescribed commercial ZULRESSO™ (brexanolone) by a physician as standard of care for postpartum depression (PPD) and who are planning to receive the infusion per United States…
- Trial name
- NCT04273191
- Testing
- Brexanolone
- Sponsor
- Sage Therapeutics
Postpartum Depressive Disorder
Quetiapine in Postpartum Depression
The purpose of the study is to evaluate the efficacy and tolerability of quetiapine in female patients with postpartum depressive disorder with psychotic symptoms
- Trial name
- NCT00681668
- Testing
- Quetiapine
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- AstraZeneca
Postpartum Depression
A Phase II Study of HS-10353 in Participants With Postpartum Depression
The primary purpose of this study is to determine if treatment with HS-10353 reduces depressive symptoms in participants with postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the 17-item…
- Trial name
- NCT05937867
- Testing
- HS-10353 Capsules 30 mg, Oral, QN for 14 days, HS-10353 Capsules 50 mg, Oral, QN for 14 days
- Volunteers
- 96 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Depression, Postpartum
A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
In this study, researchers will learn more about how zuranolone affects the symptoms of postpartum depression, also known as PPD. Zuranolone is a drug that healthcare professionals can prescribe for adults with PPD.
- Trial name
- NCT07047820
- Testing
- Zuranolone
- Where
- United States
- Volunteers
- 305 people
- Sponsor
- Biogen
Postpartum Depression
[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]
This study evaluates the efficacy of two digital therapeutics, WB001 and ED001, on depressive symptoms among women diagnosed with postpartum depression.
- Trial name
- NCT05551195
- Testing
- WB001, ED001
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Woebot Health
Depression, Postpartum
IMI PROTECT(WP2): Antidepressants & Fractures
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 and Workgroup 1.
- Trial name
- NCT01587729
- Testing
- Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Postpartum Depressive Disorder
A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum Depression
This is a study evaluating the efficacy, and safety of KH607 in 72 participants diagnosed with Postpartum Depressive Disorder.
- Trial name
- NCT07096791
- Testing
- KH607 tablet
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Postpartum Depression
A Study on the Safety, Pharmacokinetics, and Food Effects of MI078 Capsules
This study was divided into three studies, namely, a single administration study, a food impact study, and a multiple administration study.
- Trial name
- NCT06982651
- Testing
- MI078
- Where
- China
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Nanjing Minova Pharmaceutical Co., Ltd.
Severe Postpartum Depression
A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)
The primary purpose of this study is to evaluate the safety and tolerability of BRII-296 administered by 2 intramuscular injections, administered with Depo Medrol as assessed by the incidence of adverse events, changes from…
- Trial name
- NCT06057012
- Testing
- BRII-296, Depo Medrol
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brii Biosciences Limited
PostPartum Depression
Curio Digital Therapy for the Treatment of Post-partum Depression
Primary Objective: Evaluate the clinical effectiveness of the MamaLift Plus app compared to control (digital sham plus treatment as usual) for the management of PPD in the observed population for a period of 9 calendar weeks.
- Trial name
- SuMMER (NCT05958095)
- Testing
- MamaLift Plus
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Healthcare Innovation Technology Lab
Postpartum Depression
Pivotal Test: WB001
The purpose of the present randomized controlled study is to investigate if there is a difference in postpartum depression symptoms among participants assigned to : 1.
- Trial name
- NCT04576754
- Testing
- WB001, Educational
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Woebot Health
Postpartum Depression
RE104 Safety and Efficacy Study in Postpartum Depression
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.
- Trial name
- NCT06342310
- Testing
- RE104 for Injection
- Where
- 38 sites in United States
- Volunteers
- 84 people
- Sponsor
- Reunion Neuroscience Inc